DPCO Compliance for Pharma: Cost Statement Format, Ceiling Price Reporting & NPPA Rules
The Drug Price Control Order (DPCO) 2013 mandates strict cost accounting and price declaration for pharma companies. We break down cost statement format, NPPA ceiling price calculations, and critical compliance deadlines.
CA Harun Raaj
Chartered Accountant · Harun Raaj & Associates
DPCO 2013: The Compliance Framework Every Pharma Must Know
The Drug Price Control Order (DPCO) 2013, issued under the Drugs (Prices Control) Order, 1995, is the governing statute for pharmaceutical pricing in India. It applies to all manufacturers and importers of scheduled drugs. Non-compliance attracts penalties under the Essential Commodities Act, 1955, including fines and criminal prosecution. This is not optional compliance--it is statutory and strictly enforced by the National Pharmaceutical Pricing Authority (NPPA).
Scheduled vs. Non-Scheduled Drugs: What's in Scope?
DPCO applies only to scheduled drugs--those listed in the Schedule of DPCO 2013. Currently, 346 drugs across therapeutic categories fall under price control. If your product is on this list, ceiling price compliance is mandatory.
Non-scheduled drugs have pricing freedom, but you must maintain cost statements and production records if demanded by the government. Many pharma companies mistakenly assume non-scheduled drugs don't require documentation. They do--for audit trails and regulatory scrutiny.
Cost Statement Format: Section 3 Requirements
Section 3 of DPCO 2013 requires all manufacturers of scheduled drugs to file a cost statement annually with NPPA. The format is prescribed in Form 1A (for most manufacturers) and Form 1B (for imports).
Cost Statement Components:
- Raw materials consumed (with certificates of analysis and purchase invoices)
- Packing materials (direct and indirect)
- Direct labour costs (actual wages, not estimates)
- Manufacturing overheads (electricity, utilities, depreciation)
- Administrative overheads (limited to actual costs, not a percentage)
- Research and development (capitalized, not every year's cost)
- Finance costs (interest, if any)
Critical Detail: The cost statement must be filed within 120 days of the end of the preceding financial year. The NPPA also cross-checks these costs against your financial statements (profit and loss account, balance sheet). Discrepancies trigger assessments and penalties.
Many pharma companies inflate overhead allocations or use arbitrary percentage methods instead of actual costs. The NPPA auditors check your cost ledgers and general ledger accounts. Use COGS (Cost of Goods Sold) principles from Accounting Standard 2 (AS 2) or IndAS 2, whichever applies to your entity.
Ceiling Price Calculation: The Formula
The NPPA ceiling price is calculated as:
Ceiling Price = Cost of Production + Reasonable Profit Margin
The reasonable profit margin is defined in Section 3(c) of DPCO 2013 as a percentage markup on the cost of production:
- 100% markup for drugs in the anti-cancer, anti-TB, anti-HIV, and cardiac categories
- 50% markup for all other scheduled drugs
Example: If your cost of production for a paracetamol tablet is Rs. 1 per unit, the ceiling price is Rs. 1.50 (50% markup). You cannot charge above this price in the market, even if market demand permits.
Exception: If your cost of production is higher than the NPPA's estimated ceiling price (published when the drug is added to the schedule), you can apply for a cost-based exemption under Rule 6 of DPCO 2013. This requires documentary evidence and is rarely granted without strong substantiation.
Price Declaration and NPPA Submission
Once the ceiling price is calculated, you must declare your selling price to the NPPA within 30 days of the NPPA's notification or before commencing manufacture, whichever is earlier. This is done in Form 2 of DPCO 2013.
Key Points:
- Your declared price must not exceed the ceiling price
- The price applies to all customers--hospitals, retailers, wholesalers, and distributors. You cannot charge different prices to different customer categories (except for genuine trade discounts on bulk purchases, which must be transparent)
- Price revisions are permitted only when costs materially increase (typically, above 10% increase in raw material costs year-on-year)
- Price revision applications are filed in Form 3
The NPPA publishes price notifications regularly. Pharma companies often miss these notifications and continue charging old prices, creating compliance gaps.
Critical Compliance Deadlines
- Cost Statement Filing: 120 days after FY end (e.g., September 28 for FY 2024-25)
- Price Declaration: 30 days of NPPA notification
- Price Revision Applications: Anytime, but only if justifiable cost increases
- Annual Compliance Certificate: Some state authorities require annual cost certifications from your CA
Common Compliance Pitfalls
- Inflating overheads without supporting ledgers
- Using standard percentage methods instead of actual cost allocation
- Charging different prices to different customer segments
- Missing price notification updates
- Not maintaining cost ledgers for at least 3 years
- Mixing scheduled and non-scheduled drug costing into a single overhead pool
The NPPA has initiated prosecution against companies charging above ceiling prices. Penalties include confiscation of stocks, fines up to Rs. 50,000, and criminal action under the Essential Commodities Act.
What You Must Do Now
- Audit your cost statements: Verify that all overheads are actual, not estimated percentages
- Reconcile to financial statements: Cost of production in Form 1A must match your audited accounts
- Review declared prices: Cross-check against NPPA's latest notifications
- Maintain cost ledgers: Separate schedules for raw materials, overheads, labour--with supporting invoices and allocation bases
- Document price revisions: Keep filed applications and approval letters from NPPA
DPCO compliance is intricate and audited rigorously. A misstep in cost allocation or price declaration can trigger retrospective assessments, penalties, and reputational damage. Engage your CA to review your cost statements before filing and to monitor NPPA notifications quarterly.
I'm CA Harun Raaj, Visakhapatnam.
Reach out if your pharma company needs a cost statement audit or NPPA compliance review.
---
See Also
Frequently Asked Questions
What is the correct cost statement format and filing deadline for scheduled drugs under DPCO 2013?+
Section 3 of DPCO 2013 requires manufacturers to file cost statements annually in Form 1A (for most manufacturers) or Form 1B (for imports) within 120 days of the end of the preceding financial year. The cost statement must include raw materials, packing materials, direct labour, manufacturing overheads, administrative overheads, R&D, and finance costs, prepared in accordance with COGS principles from Accounting Standard 2 (AS 2) or IndAS 2.
Which drugs are covered under DPCO 2013 price control requirements?+
DPCO 2013 applies only to scheduled drugs listed in the Schedule of DPCO 2013, currently comprising 346 drugs across therapeutic categories. The order applies to all manufacturers and importers of these scheduled drugs, while non-scheduled drugs have pricing freedom but must still maintain cost statements and production records if demanded by the government.
What are the penalties for non-compliance with DPCO 2013 ceiling price reporting?+
Non-compliance with DPCO 2013 attracts penalties under the Essential Commodities Act, 1955, including fines and criminal prosecution. The National Pharmaceutical Pricing Authority (NPPA) strictly enforces compliance through cross-checking cost statements against financial statements (profit and loss account, balance sheet), with discrepancies triggering assessments and penalties.
How should pharma companies calculate and report administrative overheads in DPCO cost statements?+
Section 3 of DPCO 2013 requires administrative overheads to be limited to actual costs, not arbitrary percentage allocations. The NPPA auditors verify these costs against cost ledgers and general ledger accounts. Using estimated or inflated overhead percentages instead of actual costs is a common compliance violation that triggers NPPA assessments.
What documentation is required for raw materials in DPCO 2013 cost statement submissions?+
Under Section 3 of DPCO 2013 (Form 1A/1B requirements), raw materials consumed must be supported by certificates of analysis and purchase invoices. The NPPA cross-checks these supporting documents against your financial statements, and discrepancies in raw material costs can trigger regulatory assessments and penalties.
Are non-scheduled drugs exempt from cost statement maintenance under DPCO 2013?+
No. While non-scheduled drugs have pricing freedom under DPCO 2013, manufacturers must still maintain cost statements and production records if demanded by the government for audit trails and regulatory scrutiny. This is a common misconception among pharma companies that assume non-scheduled drugs do not require documentation.
Need help with this?
Our team handles the paperwork. You focus on your business.